|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||493.80 - 511.00|
|52-week range||493.80 - 604.50|
|PE ratio (TTM)||58.28|
|Forward dividend & yield||3.50 (0.68%)|
|1y target est||N/A|
Sun Pharma, along with other Indian pharmaceutical companies, has been battling increased competition in the generics market and greater pricing scrutiny in the United States. The drugmaker has also struggled as some of its products were banned from sale in the United States because the factories that made them did not meet U.S. quality standards. It was also hit by adjustments for U.S. tax reforms in the third quarter.
REUTERS - India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States. Along with other ...
India's largest drugmaker Sun Pharmaceutical Industries Ltd posted a surprise quarterly loss on Friday due to one-off legal costs and pressure over prices in its largest market, the United States, casting a shadow over its growth prospects. Sun is the latest maker of generic drugs to report poor sales as uncertainty grows in the global market for copycat drugs due to rising competition and pricing scrutiny in the United States. India's drugs industry, the world's fourth largest, has been hit particularly hard due also to challenges at home, where the government is tightening control over prices, and a nationwide tax reform has hit supplies.
Mumbai, Aug 11 (IANS) Sun Pharmaceutical Industries Ltd on Friday reported a huge net loss of Rs 1,291 crore for the first quarter (Q1) of fiscal 2017-18 on standalone basis, which is over eight times the net loss of Rs 152 crore incurred in the same period year ago. In a regulatory filing on the BSE, the leading drug maker said standalone revenue from operations for the quarter under review (Q1) was flat at Rs 1,803 crore as against Rs 1,800 crore in the like period year ago. Sequentially, revenue declined 11 per cent in Q1 from Rs 2,017 crore quarter ago when the net profit was Rs 95 crore.
Mumbai, June 13 (IANS) Drug major Sun Pharmaceutical Industries on Tuesday announced that one of its wholly owned subsidiaries has received final approval from the US Food and Drug Administration (USFDA) ...
India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U.S. sales might fall this year because of pressure on drug prices, signalling tough market conditions in the United States for generic drugmakers. "The U.S. generics industry is facing rapidly changing market dynamics, (and) increased competitive intensity and customer consolidation is leading to pressure on pricing," Sun's Managing Director Dilip Shanghvi said on a call with analysts after the company reported lower than expected fourth-quarter earnings.
Mumbai, May 24 (IANS) Drug major Sun Pharmaceutical Industries Ltd on Wednesday said the US Food and Drug Administration (USFDA) has accepted its Biological License Application (BLA) for tildrakizumab. In a statement issued here Sun Pharmaceuticals said the USFDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017. "The acceptance of the regulatory filing by the US FDA marks a significant milestone as we seek to advance for tildrakizumab as a potential new treatment option for people who continue to struggle everyday with the chronic nature of psoriasis," Abhay Gandhi, CEO - North America Business, Sun Pharmaceuticals, was quoted as saying in the statement.